HIV Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies), By Sponsor, By Region, And Segment Forecasts, 2025

HIV Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies), By Sponsor, By Region, And Segment Forecasts, 2025 - 2030

U.S. Vascular Access Devices Market Trends

The U.S. vascular access devices market size was estimated at USD 1.40 billion in 2024 and is expected to grow at a CAGR of 5.6% from 2025 to 2030. The market growth is driven by the increasing prevalence of chronic diseases and the growing need for medical procedures that require vascular access. As healthcare providers continue to seek efficient solutions for delivering medications, fluids, and nutrients, the demand for innovative vascular access devices is expected to rise. Additionally, advancements in technology, such as the development of antimicrobial coatings and the integration of smart technologies in vascular access devices, contribute to enhancing patient safety and improving clinical outcomes.

The rising CVD cases in the U.S. are expected to fuel the market growth. According to the American Heart Association article published in January 2024, in the U.S., CVD results in about 2,552 deaths each day. CVD patients require long-term treatments involving medications and fluids, often administered through vascular access devices like central venous catheters (CVCs) and peripherally inserted central catheters (PICCs). This growing demand for cardiovascular care is a key driver for the market, as these devices play a critical role in managing CVD effectively

The growth of the U.S. vascular access devices industry is also driven by rising use of vascular access devices among pediatric patients. For instance, in January 2024, the Population Reference Bureau had projected that the American population aged 65 and over would expand from 58 million in 2022 to 82 million by 2050, reflecting a 47% increase. Additionally, it was anticipated that the share of the total population belonging to this age bracket would grow from 17% to 23%. Older adults are easily susceptible to infectious diseases and need hospital treatment by administering parenteral nutrition (PN), which helps maintain strength, energy, and hydration.

In addition, increased cancer cases and chemotherapy demand is anticipated to drive the growth of the market. According to the National Cancer Institute, in 2024, it is projected that approximately 2,001,140 new cancer cases will be diagnosed in the United States, with an estimated 611,720 individuals expected to die from the disease. Cancer treatment, particularly chemotherapy, plays a crucial role in managing the condition. According to a Health Cost Institute article published in March 2023, nearly 1 million people in the U.S. undergo chemotherapy each year. Most of these treatments are administered via infusion or injection, often requiring patients to visit a physician’s office or hospital outpatient department.

The widespread use of infusion therapies in cancer treatment underscores the critical role of vascular access devices, such as peripherally inserted central catheters (PICCs) and central venous catheters (CVCs), in delivering chemotherapy. This growing demand for oncology care is drives the North American vascular access devices market, as these devices are essential for ensuring safe, effective, and long-term access to the bloodstream for cancer patients undergoing treatment.

U.S. Vascular Access Devices Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. vascular access devices market report based on product:

• Product Outlook (Revenue, USD Billion, 2018 - 2030)
• Central Venous Catheters (CVC)

o Tunneled CVC

o Non-Tunneled CVC

• Peripherally Inserted Central Catheter (PICCs)

o Power Injected

o Standard"
"HIV Clinical Trials Market Growth & Trends

The global HIV clinical trials market size is estimated to reach USD 2.11 billion by 2030, registering to grow at a CAGR of 5.8% from 2025 to 2030 according to a new report by Grand View Research, Inc. The main drivers of this market are increasing HIV vaccine trials, increased R&D activities for HIV clinical trials, and rising HIV infection awareness, which leads to a large number of patients enrolling in clinical trials. During the COVID-19 pandemic, there was a halt in the market growth.

This decrease in HIV and AIDS clinical trials is due to stay-at-home orders by the government to prevent COVID-19 that led to canceled and delayed trials. It also includes disruption in patient recruitment, hurdles in the conduction of clinical trials, and rapid study for the development of vaccines and medical products for the prevention of COVID-19 that lead to detrimental effects in HIV clinical trial studies. However, these impacts were significantly reduced by adopting strategic measures taken by the clinical trial conducting organization, regulatory authorities, and government bodies.

According to the WHO, in 2020, there were around 37.7 million people infected with HIV infection. To reduce this number, increasing funding and partnerships by biotechnology and pharmaceutical firms have been observed. Moreover, increasing initiatives are being taken by the government to find treatment and spread awareness regarding this disease. For instance, in October 2021, Samsung BioLogics collaborated with Enzolytics Inc. This partnership aims to manufacture Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies.

However, a lack of awareness regarding HIV clinical research trials and the availability of treatments for preventing it are factors that are hindering the growth of this market. According to a report by BioMed Central Ltd. in Europe, out of 467 participants, about one-third of them were not aware of the HIV infection. As a result, ignorance and unawareness regarding the disease will prevent admission to an HIV clinical trial.

HIV Clinical Trials Market Report Highlights

• In 2024, the phase III segment dominated the HIV clinical trials industry, accounting for a revenue share of 30.0%. Phase I studies help to assess the drug's safety & toxicity at different levels of dose & determine drug pharmacokinetics.
• In 2024, the interventional studies segment dominated the HIV clinical trials industry, accounting for a revenue share of 69.8%.
• The pharmaceutical and biopharmaceutical companies segment accounted for the largest market share in 2024.
• North America HIV clinical trials market dominated the global market in 2024 with the largest share of 47.3%. This can be attributed to the increased number of HIV clinical trials being conducted in the region.

Please note The report will be delivered in 2-3 business days upon order notification.